Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · Pharmaceutical Preparations · Redwood City, CA

Our rating: Cautious

Cautious reaffirmed at $72.77, high conviction, November 6, 2026.

Breaks if: The Cautious call is wrong if the patent invalidation is overturned on appeal AND Corcept then reports two consecutive quarters of revenue exceeding $200M with no disclosed generic market-share incursion — both conditions within 12 months from today. A legal reversal without evidence that volume is holding is insufficient; the commercial picture must confirm that exclusivity has been restored in practice, not just in court.

Key figures

Market value$7.0B
Revenue, last 12 months$964M
Net income, last 12 months$162M
Free cash flow, last 12 months$195M
Price to earnings42.9×
Free cash flow yield2.8%
Dividend yield0.0%
Operating margin11.5%
Return on equity22.1%
Beta to the S&P 5001.36
Volatility, annualized95.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$340M64.0%$1.01$142M
June 30, 2026$256M31.7%$0.36$31M
March 31, 2026$165M4.9%$-0.30−$17M
December 31, 2025$202M11.1%$0.20$38M
September 30, 2025$208M13.7%$0.16$54M
June 30, 2025$194M18.7%$0.29$44M
March 31, 2025$157M7.1%$0.17$5M
December 31, 2024$182M34.3%$0.25$60M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

24 ledger entries and 18 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.